Shiga University
13
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
15%
2 trials in Phase 3/4
13%
1 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
A Study to Evaluate the Efficacy of Anti-emetic Drug Upon the Combination Chemotherapy for Non-small Cell Lung Cancer
Role: lead
Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 Disease Controlled Advanced Non-small Cell Lung Cancer
Role: lead
Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Small Cell Lung Cancer
Role: lead
Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*02 Disease Controlled Advanced Non-small Cell Lung Cancer
Role: lead
Safety Study of Peptide Cancer Vaccine To Treat HLA-A*02-positive Advanced Non-small Cell Lung Cancer
Role: lead
Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Non-small Cell Lung Cancer
Role: lead
Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 or A*02-positive Advanced Solid Tumors
Role: lead
Night in Japan Home Sleep Monitoring Study
Role: lead
Shiga Microalbuminuria Reduction Trial-2
Role: lead
Phase II Study of S-488410 to Treat Non-small Cell Lung Cancer
Role: lead
The Effect of Sacral Surface Electrical Stimulation for Assisted Reproductive Technology
Role: lead
Shiga Progression of Diabetes, Nephropathy and Retinopathy
Role: lead
Rationale and Design for Shiga Microalbuminuria Reduction Trial
Role: lead
All 13 trials loaded